Dare Bioscience, Inc.

DARE | $0.306 3.62% 270K

(0.0% 1d) (-41.7% 1m) (-70.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 30,778,061
http://www.darebioscience.com
Sec Filling | Patents | 19 employees

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

women health women msa xaciato

add to watch list Paper trade email alert is off

Press-releases

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| 4.9% | O: 6.99% H: 0.0% C: 0.0%
bioscience contraceptive grant technology funding development

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published: 2024-04-11 (Crawled : 12:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| -37.32% | O: 1.36% H: 0.68% C: -0.64%
ovaprene test positive bioscience publication contraceptive contraception study

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| -35.19% | O: 8.01% H: 0.0% C: -5.0%
conference company year bioscience update financial results

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Published: 2024-02-22 (Crawled : 13:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| -17.08% | O: 0.88% H: 23.29% C: 20.55%
health bioscience international meeting study

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Published: 2024-01-31 (Crawled : 13:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| -8.73% | O: -2.16% H: 8.61% C: 1.06%
fda company positive bioscience meeting

Daré Bioscience Announces Executive Team and Board of Directors Changes
Published: 2024-01-26 (Crawled : 22:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| Email alert Add to watchlist
bioscience

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Published: 2024-01-17 (Crawled : 13:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| -7.41% | O: -0.31% H: 2.17% C: -1.83%
bioscience grant

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology

| -6.31% | O: -0.06% H: 10.47% C: 10.31%
device health technology potential platform

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Published: 2023-12-26 (Crawled : 13:00) - globenewswire.com
DARE | $0.306 3.62% 270K

Health Technology